intraperiton
ip
infect
infant
mice
cchf
viru
viru
titer
liver
remain
significantli
higher
organ
except
blood
serum
within
liver
viru
antigen
first
found
immunofluoresc
ifa
kupffer
cell
follow
extens
hepat
spread
later
viru
found
organ
includ
brain
heart
ribavirin
treatment
significantli
reduc
infant
mous
mortal
extend
geometr
mean
time
death
ribavirin
treatment
reduc
cchf
viru
growth
liver
significantli
decreas
prevent
viremia
despit
substanti
viremia
infect
organ
includ
brain
heart
detect
ribavirintr
mice
hepatotrop
viru
subpopul
less
neurovirul
parent
isol
liver
ribavirintr
mice
singl
dose
mgkg
serial
passag
placebotr
mice
exclus
hepatotrop
lost
infect
human
tickborn
crimeancongo
hemorrhag
fever
viru
cchf
often
result
seriou
ill
follow
death
estim
onethird
hospit
cchf
patient
die
although
mani
recov
rapidli
febril
ill
gear
case
develop
persontoperson
transmiss
via
contamin
blood
often
particularli
sever
although
clinic
indic
sever
develop
understand
ill
sever
other
etiolog
agent
cchf
singlestrand
rna
viru
nairoviru
genu
bunyavirida
famili
antigen
uniform
throughout
rang
africa
europ
asia
unusu
aspect
epidemiolog
cchf
review
detail
other
hoogstraal
watt
et
al
cchf
vaccin
avail
commerci
outsid
bulgaria
feder
commonwealth
state
administr
plasma
immun
donor
consid
standard
specif
treatment
patient
cchf
gear
howev
immunotherapi
cchf
controversi
result
inconsist
one
view
variabl
result
human
immunotherapi
trial
reflect
difficulti
get
donor
high
antibodi
titer
monath
immun
plasma
globulin
use
prophylact
suppli
limit
neutral
antibodi
titer
convalesc
plasma
low
actual
practic
patient
wellestablish
cchf
diagnosi
receiv
immun
plasma
one
studi
transient
improv
clinic
statu
note
without
clear
effect
viremia
vaneeden
et
al
limit
experi
altern
form
cchf
therapi
outbreak
cchf
tygerberg
hospit
south
africa
two
differ
antivir
agent
ribavirin
human
leukocyt
interferon
given
ribavirin
use
prophylact
six
nine
cchfcase
contact
sustain
direct
blood
exposur
variou
mean
includ
needlepunctur
three
individu
also
receiv
short
cours
interferon
six
treat
contact
one
receiv
interferon
develop
mild
case
cchf
two
three
untreat
contact
develop
sever
cchf
interpret
cloud
fact
one
untreat
contact
addit
untreat
individu
contact
contamin
blood
develop
diseas
vandew
et
al
south
african
patient
treat
high
dose
human
leukocyt
interferon
either
prophylact
therapeut
togeth
plasma
develop
sever
sideeffect
practic
stop
vandew
et
al
six
year
later
brief
report
given
result
treat
cchf
patient
ribavirin
openlabel
trial
south
africa
swanepoel
et
al
ribavirin
therapi
start
earli
day
postonset
none
seven
patient
die
howev
seven
survivor
two
clinic
laboratori
marker
associ
mortal
histor
control
late
initi
therapi
day
postonset
three
five
patient
die
purpos
research
studi
effect
ribavirin
laboratori
model
cchf
viru
infect
outbreak
cchf
unpredict
sudden
frequent
enough
enough
serious
warrant
antivir
drug
studi
howev
laboratori
anim
model
cchf
infect
difficult
establish
frequent
use
laboratori
anim
show
littl
sign
infect
diseas
gear
also
laboratori
work
cchf
limit
accident
infect
seriou
even
fatal
outcom
frequent
occur
cdc
result
littl
known
pathogenet
mechan
govern
express
human
diseas
cchf
infect
done
similar
situat
candid
compound
ribavirin
experiment
model
examin
studi
grunert
experiment
model
use
experi
infant
mous
model
base
intraperiton
ip
inocul
cchf
viru
ribavirin
suppli
dr
john
huggin
depart
antivir
studi
virolog
divis
us
armi
medic
research
institut
infecti
diseas
frederick
maryland
either
mgkg
dose
inocul
intraperiton
ip
infant
mice
volum
ml
rain
later
viru
inocul
ip
volum
ml
viru
passag
level
infant
mous
tissu
cchf
strain
ibar
isol
nigeria
describ
previous
placebotr
mice
inocul
dulbecco
minim
essenti
medium
dmem
diluent
drug
viru
titrat
simultan
multipl
drug
dose
test
total
four
daili
drug
dose
given
inject
viru
infect
mice
hous
observ
daili
biosafeti
level
anim
facil
modifi
especi
work
sentinel
mice
test
serolog
intercurr
murin
infect
yale
univers
divis
anim
care
class
biolog
safeti
cabinet
use
biolog
safeti
level
laboratori
manipul
involv
infecti
potenti
infecti
materi
individu
worker
equip
hepafilt
respir
underw
serolog
surveil
throughout
cours
project
geometr
mean
time
death
calcul
placebotr
mice
drugtreat
mice
geometr
mean
time
death
gmtd
equal
nth
root
n
total
number
anim
product
day
mortal
rais
power
number
anim
die
day
calcul
surviv
defin
day
correl
statist
signific
differ
drugand
placebotr
group
determin
standard
test
describ
earlier
use
systat
wilkinson
direct
measur
ribavirin
effect
mous
mortal
use
comparison
gmtd
case
log
protect
index
pi
calcul
determin
subtract
log
viru
titer
drugtreat
anim
log
ldso
viru
titer
placebotr
anim
log
protect
index
meant
least
protect
viru
techniqu
wide
use
determin
protect
mediat
virusneutr
antibodi
shope
placebotr
ribavirintr
mice
divid
two
group
one
mice
held
observ
viru
titrat
daili
group
inocul
cer
cell
blood
serum
liver
brain
spleen
heart
tissu
homogen
cell
suppli
dr
watt
us
armi
medic
research
institut
infecti
diseas
also
use
test
tissu
eight
anim
pool
examin
four
replic
cultur
interv
mice
first
exsanguin
perfus
dmem
tissu
remov
weigh
homogen
clarifi
light
centrifug
supernat
fluid
inocul
freshli
made
cultur
describ
earlier
pathogenesi
experi
tignor
et
al
viru
titer
determin
fluoresc
assay
infect
cell
semisolid
overlay
express
ffuinoculum
describ
earlier
variat
individu
titer
less
logm
infect
tissu
also
examin
immunofluoresc
tissu
section
mice
cut
thick
mount
fix
aceton
stain
cchf
control
rabi
viru
antibodi
wash
pb
stain
fluoresceinconjug
goat
antimous
antibodi
antibodi
incorpor
davi
ca
coloc
viru
specif
cell
type
peroxidas
stain
paraffinembed
tissu
use
commerci
kit
extravidin
biotin
stain
kit
sigma
st
loui
mo
virusspecif
cellspecif
monoclon
polyclon
antibodi
maci
antibodi
monoclon
antibodi
clone
surfac
antigen
found
mous
macrophag
cell
purchas
commerci
boehringermannheim
biochem
indianapoli
antibodi
describ
weakli
reactiv
liver
tissu
macrophag
ho
springer
prepar
use
cchf
viru
polyclon
antibodi
ifa
neutral
test
earlier
describ
antibodi
immunofluoresc
observ
includ
describ
earlier
public
other
refer
collect
yale
arboviru
research
unit
bandia
bwamba
california
enceph
caraparu
chenuda
chikungunya
colorado
tick
fever
dengu
dhori
dugb
germiston
hazara
japanes
enceph
kemerovo
lymphocyt
choriomening
napl
sandfli
fever
oropouch
qalyub
rabi
sindbi
venezuelan
equin
enceph
wad
medani
west
nile
yellow
fever
neutral
test
monitor
puriti
ident
viru
isol
necropsi
perform
use
constant
antibodi
vari
viru
dilut
protocol
mice
escap
neutral
ie
breakthough
mice
examin
ifa
establish
ident
viru
tissu
hybridoma
produc
monoclon
neutral
anticchf
antibodi
prepar
intrasplen
inocul
viru
use
otherwis
standard
method
spitz
et
al
kohler
milstein
monoclon
antibodi
isotyp
use
commerci
kit
zyme
laboratori
san
francisco
ca
screen
done
ifa
immunoprecipit
carri
describ
elsewher
hanham
et
al
placebotr
anim
invers
relationship
correl
coeffici
r
geometr
mean
time
death
gmtd
cchf
viru
dose
higher
viru
dose
less
correl
gmtd
mice
kill
less
day
ip
inocul
regardless
viru
dose
use
dose
viru
frozen
viru
stock
test
gmtd
rang
day
day
mean
given
singl
dose
earli
infect
ribavirin
effect
treatment
dose
low
mgkg
cchf
model
test
use
exact
viru
dose
mean
gmtd
day
increas
day
p
use
constant
mgkg
dose
ribavirin
direct
relationship
correl
coeffici
r
exist
ribavirin
gmtd
viru
dose
lowest
increas
gmtd
day
greatest
tabl
use
viru
gmtd
multipl
ribavirin
dose
mgkg
day
higher
singl
dose
gmtd
multipl
inject
mgkg
howev
singl
mgkg
dose
nearli
effect
multipl
dose
mg
kg
tabl
begin
treatment
day
earliest
time
onset
clinic
sign
effect
either
mortal
gmtd
gmtd
compar
log
protect
effect
pi
pi
direct
measur
reduc
mortal
attribut
ribavirin
treatment
correl
coeffici
r
increas
gmtd
day
rang
equival
pi
data
base
chang
gmtd
experi
done
ip
cchf
viru
infect
infant
mice
viru
replic
first
detect
liver
subsequ
spread
blood
serum
viru
titer
slightli
higher
liver
serum
fig
day
day
last
surviv
day
placebotr
mice
rel
viru
growth
liver
tissu
viru
appear
late
infect
tissu
includ
brain
day
fig
heart
day
fig
ib
viru
isol
spleen
day
fig
viru
titer
higher
liver
organ
possibl
except
serum
differ
viru
titer
liver
brain
heart
spleen
signific
p
pair
ttest
howev
differ
titer
liver
serum
statist
signific
ribavirintr
mice
singl
dose
mgkg
significantli
lower
viru
titer
liver
pair
ttest
fig
significantli
reduc
viremia
pair
ttest
fig
although
viru
growth
liver
suppress
ribavirin
treatment
larg
viremia
detect
begin
day
despit
viremia
viru
isol
heart
spleen
brain
none
treat
mice
held
observ
die
experi
mice
examin
day
later
placebotr
anim
cchf
viru
antigen
present
mani
cluster
hepatocyt
wide
distribut
throughout
liver
tissu
includ
occasion
tissu
macrophag
infect
kupffer
cell
promin
fig
cchf
antigen
spars
seen
liver
tissu
ribavirintr
anim
sometim
put
kupffer
cell
sometim
hepatocyt
also
posit
anticchf
antibodi
day
fig
experi
describ
evid
cchf
viru
infect
liver
found
appar
healthi
ribavirintr
mice
despit
b
follow
infect
organ
brain
heart
result
suggest
protect
effect
singl
dose
ribavirin
mgkg
diminish
time
therefor
experi
repeat
focus
viremia
ribavirintr
mice
use
higher
ribavirin
dose
mgkg
addit
dose
ribavirin
given
day
viru
isol
done
day
viremia
loglo
ffuml
found
day
continu
level
day
day
titer
ffuml
decreas
viru
found
day
despit
rel
prolong
viremia
viru
isol
liver
day
brain
heart
spleen
titer
liver
viru
determin
mice
held
observ
die
liver
tissu
cchf
virusinfect
ribavirintr
mice
singl
dose
mgkg
titrat
daili
ip
subinocul
infant
mice
peak
titer
liver
found
day
eight
ribavirintr
mice
singl
dose
mgkg
without
clinic
sign
ill
necropsi
eighth
day
ip
viru
inject
viru
found
pool
serum
supernat
fluid
tissu
homogen
pool
liver
organ
includ
brain
heart
spleen
infecti
viru
titer
liver
serum
determin
ip
inocul
infant
mice
viru
liver
tissu
ribavirintr
mice
grew
poorli
cer
cell
exampl
individu
well
labtek
slide
tray
contain
x
cer
cell
posit
cell
observ
ifa
result
similar
cell
residu
ribavirin
tissu
homogen
could
inhibit
viru
growth
vitro
therefor
viru
pellet
supernat
fluid
ultracentrifug
x
g
rain
viru
infect
cultur
cer
cell
increas
variabl
individu
cultur
number
infect
cell
imposs
determin
vitro
ribavirin
sensit
reliabl
attempt
made
determin
ribavirin
sensit
vivo
origin
liver
tissu
viru
ribavirintr
mice
use
sourc
vivo
ribavirin
drug
test
mice
infect
liver
viru
ip
treat
singl
dose
ribavirin
either
mgkg
gmtd
mice
treat
mgkg
unchang
placebo
control
mortal
gmtd
mice
treat
mgkg
increas
day
mortal
eight
eight
placebotr
anim
die
gmtd
day
viru
isol
done
ip
inocul
infant
mice
use
pool
tissu
two
mice
taken
day
two
group
one
treat
mgkg
one
placebotr
viru
isol
liver
serum
treat
placebotr
mice
day
organ
either
day
treat
mice
mgkg
viru
titer
logio
follow
day
liver
serum
day
liver
serum
viru
titer
placebo
mice
follow
day
liver
serum
day
liver
serum
data
show
ribavirin
treatment
mgkg
reduc
viru
titer
treat
anim
contrast
earlier
experi
parent
viru
treatment
ribavirin
mgkg
effect
viru
titer
data
shown
despit
rel
high
viremia
placebotr
mice
viru
isol
tissu
brain
heart
spleen
suggest
mark
hepatotrop
inject
viru
three
blind
passag
hepatotrop
viru
placebotr
mice
result
loss
strict
hepatotrop
three
ip
passag
liver
tissu
viru
harvest
day
sick
infect
mice
necropsi
isol
viru
follow
titer
loglo
liver
serum
brain
heart
strict
hepat
tropism
longer
evid
tissu
mice
infect
liver
viru
ribavirintr
anim
examin
immunofluoresc
use
batteri
antivir
antibodi
list
materi
method
antibodi
mous
hepat
viru
mhv
also
includ
viru
common
contamin
mous
coloni
infect
kupffer
cell
unaffect
ribavirin
ruebner
miyai
robin
posit
reaction
cchf
viru
antibodi
addit
divis
anim
care
yale
school
medicin
report
serolog
evid
mhv
infect
sentinel
anim
hous
anim
facil
ident
puriti
establish
mous
neutral
test
use
cchf
viru
mous
monoclon
antibodi
monoclon
antibodi
igg
react
immunoprecipit
singl
radiolabel
cchf
viru
protein
fig
neutral
titer
ip
mous
neutral
test
use
ldso
cchf
viru
breakthrough
neutral
test
done
constant
amount
antibodi
vari
dilut
viru
breakthrough
mice
show
clinic
sign
ill
die
neutral
test
purpos
research
test
ribavirin
vivo
laboratori
model
antivir
activ
diseas
caus
cchf
viru
avail
vivo
system
infant
mous
model
viru
caus
clinic
sign
diseas
commonli
use
laboratori
anim
unfortun
possibl
find
ribavirin
may
directli
applic
primat
metabol
ribavirin
rodent
differ
primat
catlin
et
al
ferrara
et
al
model
provid
interest
observ
viru
tropism
remark
specif
cchf
viru
tissu
tropism
infant
mice
broad
respect
demonstr
pathogenesi
similar
known
aspect
human
rel
earli
associ
cchf
viru
kupffer
cell
hepatocyt
found
model
bear
relev
human
diseas
seri
publish
autopsi
find
summar
hoogstraal
hoogstraal
extens
patholog
examin
mani
case
fatal
cchf
infect
period
karmysheva
conclud
cchf
viru
multipli
cell
especi
kupffer
cell
reticuloendotheli
system
specif
antigen
detect
immunofluoresc
gear
describ
cchf
liver
diseas
gear
swanepoel
et
al
found
prolong
viremia
maximum
titer
found
logm
ffuml
necrot
lesion
five
seven
liver
specimen
taken
deceas
patient
also
found
patient
die
develop
termin
multipl
organ
failur
includ
cerebr
liver
among
other
model
viru
growth
brain
organ
termin
event
despit
rather
prolong
viremia
murin
coronavirus
arbovirus
liver
tropism
infant
mice
similar
shown
experi
ruebner
miyai
shope
causey
gone
elabor
length
elimin
intercurr
infect
contamin
reagent
explan
experiment
result
develop
use
cchf
viru
neutral
monoclon
antibodi
confirm
ident
viru
one
step
establish
puriti
ident
ribavirin
treatment
murin
model
effect
increas
geometr
mean
time
death
treat
anim
reduc
frequenc
clinic
sign
mortal
demonstr
ribavirin
efficaci
vivo
total
unexpect
ribavirin
shown
vitro
activ
cchf
mani
bunyavirus
review
huggin
monath
nevertheless
vitro
vivo
efficaci
alway
correl
case
yellow
fever
viru
vitro
effect
vero
cell
duplic
vivo
protect
primat
huggin
although
drug
efficaci
establish
suppress
liver
cell
infect
viremia
continu
rel
long
period
appar
healthi
ribavirintr
anim
examin
case
liver
infect
appar
selflimit
subsequ
mortal
anim
held
observ
prolong
depress
viremia
ribavirin
treatment
also
occur
lassa
fever
virusinfect
anim
ultim
surviv
mccormick
et
al
sourc
viremia
describ
may
also
liver
base
upon
diseas
sign
symptom
sourc
prolong
suppress
viremia
experi
appar
liver
cchf
viru
isol
liver
ribavirintr
anim
exclus
hepatotrop
limit
passag
placebotr
ribavirintr
mice
parent
viru
infect
organ
liver
serum
vivo
grow
well
cer
cell
vitro
brain
rel
spare
ip
inocul
put
subpopul
appear
less
neurovirul
infant
mice
parent
viru
unusu
result
drugselect
mutant
studi
sometim
less
virul
parent
viru
field
coen
present
data
suggest
viru
propag
liver
cchf
virusinfect
ribavirintr
mice
dose
regimen
singl
dose
mgkg
parent
viru
reduc
viru
titer
mortal
ineffect
use
viru
harvest
fiom
liver
ribavirintr
anim
nevertheless
increas
dose
drug
singl
dose
mgkg
inde
substanti
reduc
viru
titer
liver
serum
even
though
mortal
reduc
repeat
passag
liver
viru
ribavirintr
mice
multipl
dose
mgkg
result
loss
infect
latter
two
observ
suggest
partial
resist
appar
may
real
seen
partial
resist
model
may
relat
pharmacolog
properti
ribavirin
uniqu
infant
mous
tissu
exampl
infant
mous
liver
cell
could
becom
resist
effect
low
dose
drug
therebi
make
sensit
viru
appear
resist
postul
elsewher
herrmann
herrmann
moreov
resist
ribavirin
never
describ
unlik
case
antivir
acyclovir
idoxuridin
bvdu
prevail
concept
resist
ribavirin
unlik
develop
drug
show
multipl
site
antivir
action
hall
et
al
wilson
et
al
review
gilbert
knight
huggin
theori
resist
like
happen
narrowspectrum
viral
inhibitor
act
inhibit
singl
viral
enzym
hall
et
al
wilson
et
al
review
gilbert
knight
huggin
report
inabl
isol
resist
mutant
stimul
question
technic
classifi
antivir
agent
herrmann
herrmann
factor
direct
antivir
effect
postul
account
appar
antivir
efficaci
compound
yet
avail
evid
suggest
host
cell
specif
antivir
effect
detail
studi
antivir
effect
ribavirin
done
influenza
virus
review
gilbert
knight
well
establish
ribavirin
chang
cellular
purin
nucleotid
metabol
inhibit
inosin
monophosph
dehydrogenas
key
enzym
synthesi
guanosin
nucleotid
howev
also
evid
ribavirininduc
inhibit
influenza
viru
rnapolymeras
one
hand
eriksson
et
al
mrnacap
enzym
guanylrnatransferas
goswami
et
al
also
suggest
ribavirin
inhibit
influenza
viru
vrnapolymeras
specif
mechan
decreas
cellular
gtp
pool
wray
et
al
nevertheless
effort
develop
ribavirin
resist
mutant
influenza
viru
unsuccess
field
methodolog
use
anim
model
similar
use
defin
poxviru
resist
thiosemicarbazon
appleyard
way
amantadineresist
influenza
oxford
et
al
acyclovirresist
mutant
herp
simplex
viru
field
howev
use
similar
methodolog
produc
conclus
evid
cchf
viru
resist
ribavirin
develop
rather
hypothesi
consist
ribavirin
pathogenesi
experi
ribavirin
treatment
infect
infant
mice
transient
select
cchf
viru
subpopul
highli
hepatotrop
parent
viru
may
ribavirininduc
select
viru
subpopul
enhanc
tropism
particular
target
organ
occur
elsewher
ribavirin
treatment
machupo
viru
arenaviru
infect
rhesu
monkey
viremia
significantli
reduc
fact
day
viremia
detect
nevertheless
treat
anim
die
treat
anim
die
late
neurolog
syndrom
seen
infect
placebotr
control
anim
presum
late
neurolog
phase
diseas
result
inabl
ribavirin
concentr
cn
primari
concern
also
possibl
viru
subpopul
greater
tropism
cn
initi
surviv
ribavirin
treatment
dosag
use
contribut
diseas
process
cchf
viru
infant
mous
model
viru
subpopul
isol
ribavirintr
mice
less
neurotrop
infant
mice
parent
popul
studi
subpopul
remark
homogen
tropism
may
provid
insight
virushost
cell
interact
relat
organ
tropism
past
drugselect
viru
variant
use
type
research
field
coen
